In Vitro Models of Ovarian Cancer: Bridging the Gap Between Pathophysiology and Mechanistic Models
Overview
Molecular Biology
Authors
Affiliations
Ovarian cancer (OC) is a disease of major concern with a survival rate of about 40% at five years. This is attributed to the lack of visible and reliable symptoms during the onset of the disease, which leads over 80% of patients to be diagnosed at advanced stages. This implies that metastatic activity has advanced to the peritoneal cavity. It is associated with both genetic and phenotypic heterogeneity, which considerably increase the risks of relapse and reduce the survival rate. To understand ovarian cancer pathophysiology and strengthen the ability for drug screening, further development of relevant in vitro models that recapitulate the complexity of OC microenvironment and dynamics of OC cell population is required. In this line, the recent advances of tridimensional (3D) cell culture and microfluidics have allowed the development of highly innovative models that could bridge the gap between pathophysiology and mechanistic models for clinical research. This review first describes the pathophysiology of OC before detailing the engineering strategies developed to recapitulate those main biological features.
Cancer Organoids as reliable disease models to drive clinical development of novel therapies.
Blandino G, Satchi-Fainaro R, Tinhofer I, Tonon G, Heilshorn S, Kwon Y J Exp Clin Cancer Res. 2024; 43(1):334.
PMID: 39731178 PMC: 11681695. DOI: 10.1186/s13046-024-03258-7.
Plesselova S, Calar K, Axemaker H, Sahly E, Bhagia A, Faragher J Cell Mol Bioeng. 2024; 17(5):345-367.
PMID: 39513004 PMC: 11538101. DOI: 10.1007/s12195-024-00817-y.
Scott A, Jazwinska D, Kulawiec D, Zervantonakis I Adv Healthc Mater. 2024; 13(28):e2401719.
PMID: 38807270 PMC: 11560735. DOI: 10.1002/adhm.202401719.
Vascularized tumor models for the evaluation of drug delivery systems: a paradigm shift.
Lopez-Vince E, Wilhelm C, Simon-Yarza T Drug Deliv Transl Res. 2024; 14(8):2216-2241.
PMID: 38619704 PMC: 11208221. DOI: 10.1007/s13346-024-01580-3.
Revolutionizing the female reproductive system research using microfluidic chip platform.
Yan J, Wu T, Zhang J, Gao Y, Wu J, Wang S J Nanobiotechnology. 2023; 21(1):490.
PMID: 38111049 PMC: 10729361. DOI: 10.1186/s12951-023-02258-7.